1.Prototype single-balloon enteroscopy with passive bending and high force transmission improves depth of insertion in the small intestine
Yasuhiro MORITA ; Shigeki BAMBA ; Osamu INATOMI ; Kenichiro TAKAHASHI ; Takayuki IMAI ; Masaki MURATA ; Masashi OHNO ; Masaya SASAKI ; Tomoyuki TSUJIKAWA ; Akira ANDOH
Intestinal Research 2020;18(2):229-237
Background/Aims:
We retrospectively analyzed Crohn’s disease (CD) patients with small intestinal strictures who underwent single-balloon enteroscopy (SBE) to ascertain whether prototype SBEs with a passive bending mechanism and high force transmission insertion tube had better insertability in the small intestine than a conventional SBE.
Methods:
Among 253 CD patients who underwent SBE, we identified 94 CD patients who had undergone attempted endoscopic balloon dilatation (EBD) for small intestinal stenosis for inclusion in this study. We analyzed whether the type of scope used for their initial procedure affected the cumulative surgery-free rate. For the insertability analysis, patients who underwent SBE at least twice were divided into 3 groups according to the type of scope used: conventional SBE only, prototype SBE only, and both conventional and prototype SBEs. For each group, depth of insertion, procedure time, and number of EBDs were compared in the same patient at different time points.
Results:
The success rate of EBD was 88.3%. The 5- and 10-year cumulative surgery-free rate was 75.7% and 72.8%, respectively. Cox regression analysis indicated that the factors contributing to surgery were long stricture (≥2 cm), EBD failure, and elevated Crohn’s Disease Activity Index, but not the type of scope used for EBD. The prototype SBEs significantly improved the depth of insertion (P=0.03, Wilcoxon’s signed-rank test).
Conclusions
In CD patients with small intestinal stenosis, the prototype SBEs with a passive bending mechanism and high force transmission insertion tube did not improve long-term EBD outcome but did improve deep insertability. (Clinical Trial Registration No. UMIN000037102)
2.Magnified single-balloon enteroscopy in the diagnosis of intestinal follicular lymphoma: a case series.
Kenichiro TAKAHASHI ; Shigeki BAMBA ; Masahiro KAWAHARA ; Atsushi NISHIDA ; Osamu INATOMI ; Masaya SASAKI ; Tomoyuki TSUJIKAWA ; Ryoji KUSHIMA ; Mitsushige SUGIMOTO ; Katsuyuki KITOH ; Akira ANDOH
Intestinal Research 2018;16(4):628-634
The objective of this study was to evaluate the magnified endoscopic findings in the diagnosis of follicular lymphoma in the small intestine in comparison with those of intestinal follicular lymphoma and lymphangiectasia. Four patients with follicular lymphoma and 3 with lymphangiectasia in the small intestine were retrospectively analyzed. A prototype magnifying singleballoon enteroscope was used. The findings of the intestinal follicular lymphoma and lymphangiectasia were retrospectively analyzed to determine the magnified endoscopic findings of follicular lymphoma in the small intestine. Opaque white granules were observed in 3 of the 4 patients with follicular lymphoma. Magnified narrow-band imaging (NBI) of the opaque white granules showed stretched microvessels, which had a diminutive tree-like appearance. The remaining patient had no opaque white granules and only displayed whitish villi. Magnified NBI observation of the whitish villi revealed the absence of marginal villus epithelium, which was confirmed by histology. The magnified NBI enteroscopy revealed the diminutive tree-like appearance on the opaque white granules and the absence of marginal villus epithelium of the whitish villi in intestinal follicular lymphoma. These findings may be useful in diagnosing follicular lymphoma.
Diagnosis*
;
Epithelium
;
Humans
;
Intestine, Small
;
Lymphoma, Follicular*
;
Microvessels
;
Narrow Band Imaging
;
Retrospective Studies
3.Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial.
Tadakazu HISAMATSU ; Reiko KUNISAKI ; Shiro NAKAMURA ; Tomoyuki TSUJIKAWA ; Fumihito HIRAI ; Hiroshi NAKASE ; Kenji WATANABE ; Kaoru YOKOYAMA ; Masakazu NAGAHORI ; Takanori KANAI ; Makoto NAGANUMA ; Hirofumi MICHIMAE ; Akira ANDOH ; Akihiro YAMADA ; Tadashi YOKOYAMA ; Noriko KAMATA ; Shinji TANAKA ; Yasuo SUZUKI ; Toshifumi HIBI ; Mamoru WATANABE
Intestinal Research 2018;16(3):494-498
No abstract available.
Crohn Disease*
;
Food, Formulated*
;
Humans
;
Infliximab*
4.Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Taku KOBAYASHI ; Tadakazu HISAMATSU ; Yasuo SUZUKI ; Haruhiko OGATA ; Akira ANDOH ; Toshimitsu ARAKI ; Ryota HOKARI ; Hideki IIJIMA ; Hiroki IKEUCHI ; Yoh ISHIGURO ; Shingo KATO ; Reiko KUNISAKI ; Takayuki MATSUMOTO ; Satoshi MOTOYA ; Masakazu NAGAHORI ; Shiro NAKAMURA ; Hiroshi NAKASE ; Tomoyuki TSUJIKAWA ; Makoto SASAKI ; Kaoru YOKOYAMA ; Naoki YOSHIMURA ; Kenji WATANABE ; Miiko KATAFUCHI ; Mamoru WATANABE ; Toshifumi HIBI
Intestinal Research 2018;16(2):168-177
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
Asian Continental Ancestry Group
;
Colectomy
;
Colitis, Ulcerative
;
Colorectal Neoplasms
;
Consensus
;
Crohn Disease
;
Disease Management*
;
Disease Progression
;
Early Intervention (Education)
;
Epidemiology
;
Expert Testimony
;
Gastrointestinal Tract
;
Hospitalization
;
Humans
;
Inflammatory Bowel Diseases*
;
Japan*
;
Prevalence
;
Prognosis